As of 2021, there has been no reported recurrence of ectopic papillary hidradenomas. Prognosis after complete surgical removal of anogenital and ectopic papillary hidradenomas is excellent. Malignant transformation of papillary hidradenomas
Transformations of papillary hidradenomas into malignant forms are extremely rare. Two cases progressed to in situ (malignant cells present in the tumor but have neither metastasized, i.e. spread to distant tissues nor invaded beyond the layer of tissue from where they arose) cancers; two cases appeared to have infiltrated locally but not metastasized; and one case was a rapidly fatal lesion that appeared to be an adenosquamous carcinoma that arose in a papillary hidradenoma. It is not clear that these cases actually represent true progression of papillary hidradenoma into a cancer. See also
Hidroacanthoma simplex
List of cutaneous conditions

References


== External links ==
Bazedoxifene/conjugated estrogens, sold under the brand name Duavee in the US and Duavive in the EU, is a fixed-dose combination medication for the treatment of menopause symptoms and postmenopausal osteoporosis. It contains the selective estrogen receptor modulator bazedoxifene and conjugated estrogens. It is taken by mouth. The combination was approved for medical use in the United States in October 2013, and in the European Union in December 2014. See also
List of combined sex-hormonal preparations

References
External links
"Bazedoxifene mixture with conjugated estrogens". Drug Information Portal. U.S. National Library of Medicine.